Iron and multiple sclerosis

Neurobiology of Aging

Volumn 35, Issue SUPPL.2, 2014, Pages

  Stankiewicz, James M ^a   Neema, Mohit ^a   Ceccarelli, Antonia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antioxidant; Brain; Chelation; Iron; Multiple sclerosis

Indexed keywords

ANTIOXIDANT; DEFEROXAMINE; FUMARIC ACID DIMETHYL ESTER; HYDROGEN PEROXIDE; IRON; IRON CHELATING AGENT; TRANSFERRIN RECEPTOR; ALPHA TOCOPHEROL; GLUTATHIONE;

BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN LEVEL; DRUG EFFICACY; DRUG SAFETY; GRAY MATTER; HOMEOSTASIS; HUMAN; INTESTINE ABSORPTION; INTRACELLULAR TRANSPORT; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WHITE MATTER; AGING; BRAIN; CYTOLOGY; METABOLISM; NERVE CELL; PATHOLOGY; TISSUE DISTRIBUTION; CLINICAL TRIAL (TOPIC); IRON DEPOSITION; IRON DISTRIBUTION; IRON HOMEOSTASIS; IRON METABOLISM; IRON TRAFFICKING; PATHOGENESIS;

AGING; ANTIOXIDANTS; BRAIN; HUMANS; IRON; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEURONS; TISSUE DISTRIBUTION;

EID: 84903689569     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.039     Document Type: Review

References (90)

1. Adams C.W. Perivascular iron deposition and other vascular damage in multiple sclerosis. J.Neurol. Neurosurg. Psychiatry 1988, 51:260-265.
2. Aguirre P., Mena N., Tapia V., Rojas A., Arrendondo N., Núñez M.T. Antioxidant responses of cortex neurons to iron loading. Biol. Res. 2006, 39:103-104.
3. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.M., Infante-Duarte C., Brocke S., Zipp E. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J.Immunol. 2004, 173:5794-5800.
4. Al-Radaideh A.M., Wharton S.J., Lim S.Y., Tench C.R., Morgan P.S., Bowtell R.W., Constantinescu C.S., Gowland P.A. Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in clinically isolated syndrome. Mult. Scler. 2013, 19:896-903.
5. Aoki S., Okada Y., Nishimura K., Barkovich A.J., Kjos B.O., Brasch R.C., Norman D. Normal deposition of brain iron in childhood and adolescence: MRI imaging at 1.5T. Radiology 1989, 172:381-385.
6. Bagnato F., Hametner S., Welch E.B. Visualizing iron in multiple sclerosis. Magn. Reson. Imaging 2013, 31:376-384.
7. Bagnato F., Hametner S., Yao B., van Gelderen P., Merkle H., Cantor F.K., Lassmann H., Duyn J.H. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011, 134:3602-3615.
8. Bakshi R., Benedict R.H., Bermel R.A., Caruthers S.D., Puli S.R., Tjoa C.W., Fabiano A.J., Jacobs L. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch. Neurol. 2002, 59:62-68.
9. Bakshi R., Dmochowski J., Shaikh Z.A., Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J.Neurol. Sci. 2001, 185:19-26.
10. Bakshi R., Shaikh Z.A., Janardhan V. MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000, 11:15-21.
11. Beard J. Iron deficiency alters brain development and functioning. J.Nutr. 2003, 133:1468S-1472S.
12. Benarroch E.E. Brain iron homeostasis and neurodegenerative disease. Neurology 2009, 72:1436-1440.
13. Bermel R.A., Puli S.R., Rudick R.A., Weinstock-Guttman B., Fisher E., Munschauer F.E., Bakshi R. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch. Neurol. 2005, 62:1371-1376.
14. Bian W., Harter K., Hammond-Rosenbluth K.E., Lupo J.M., Xu D., Kelley D.A., Vigneron D.B., Nelson S.J., Pelletier D. Aserial invivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult. Scler. 2013, 19:69-75.
15. Bowern N., Ramshaw I., Clark I., Doherty P. Inhibition of autoimmune neuropathological process by treatment with an iron chelating agent. J.Exp. Med. 1984, 160:1532-1543.
16. Brass S.D., Benedict R.H., Weinstock-Guttman B., Munschauer F., Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult. Scler. 2006, 12:437-444.
17. Brass S.D., Chen N.K., Mulkern R.V., Bakshi R. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn. Reson. Imaging 2006, 17:31-40.
18. Ceccarelli A., Filippi M., Neema M., Arora A., Valsasina P., Rocca M.A., Healy B.C., Bakshi R. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult. Scler. 2009, 15:678-686.
19. Ceccarelli A., Rocca M.A., Neema M., Martinelli V., Arora A., Tauhid S., Ghezzi A., Comi G., Bakshi R., Filippi M. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult. Scler. 2010, 16:39-44.
20. Ceccarelli A., Rocca M.A., Perego E., Moiola L., Ghezzi A., Martinelli V., Comi G., Filippi M. Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. Mult. Scler. 2011, 17:702-707.
21. Craelius W., Migdal M.W., Luessenhop C.P., Sugar A., Mihalakis I. Iron deposits surrounding multiple sclerosis plaques. Arch. Pathol. Lab. Med. 1982, 106:397-399.
22. Crichton R.R., Wilmet S., Legssyer R., Ward R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J.Inorg. Biochem. 2002, 91:9-18.
23. Dautry-Varsat A., Ciechanover A., Lodish H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U.S.A 1983, 80:2258-2262.
24. De Domenico I., McVey Ward D., Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat. Rev. Mol. Cell Biol. 2008, 9:72-81.
25. de Jesus Ferreira M.C., Crouzin N., Barbanel G., Cohen-Solal C., Récasens M., Vignes M., Guiramand J. Atransient treatment of hippocampal neurons with alpha-tocopherol induces a long-lasting protection against oxidative damage via a genomic action. Free Radic. Biol. Med. 2005, 39:1009-1020.
26. Drayer B., Burger P., Hurwitz B., Dawson D., Cain J. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?. AJR Am. J. Roentgenol. 1987, 149:357-363.
27. Drayer B.P., Burger P., Hurwitz B., Dawson D., Cain J., Leong J., Herfkens R., Johnson G.A. Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann. Neurol. 1987, 22:546-550.
28. Eissa A., Lebel R.M., Korzan J.R., Zavodni A.E., Warren K.G., Catz I., Emery D.J., Wilman A.H. Detecting lesions in multiple sclerosis at 4.7 tesla using phase susceptibility-weighting and T2-weighting. J.Magn. Reson. Imaging 2009, 30:737-742.
29. Fiebiger S.M., Bros H., Grobosch T., Janssen A., Chanvillard C., Paul F., Dörr J., Millward J.M., Infante-Duarte C. The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. J.Neuroimmunol. 2013, 262:66-71.
30. Ge Y., Jensen J.H., Lu H., Helpern J.A., Miles L., Inglese M., Babb J.S., Herbert J., Grossman R.I. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am. J. Neuroradiol. 2007, 28:1639-1644.
31. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J.Neurol. 2004, 251:261-268.
32. Gonsette R.E., Sindic C., D'hooghe M.B., De Deyn P.P., Medaer R., Michotte A., Seeldrayers P., Guillaume D. Neuroprotection in multiple sclerosis: the Association of Inosine and Interferon ASIIMS study group. Boosting endogenous beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. Mult. Scler. 2010, 16:455-462.
33. Haacke E.M., Cheng N.Y., House M.J., Liu Q., Neelavalli J., Ogg R.J., Khan A., Ayaz M., Kirsch W., Obenaus A. Imaging iron stores in the brain using magnetic resonance imaging. Magn. Reson. Imaging 2005, 23:1-25.
34. Haacke E.M., Makki M., Ge Y., Maheshwari M., Sehgal V., Hu J., Selvan M., Wu Z., Latif Z., Xuan Y., Khan O., Garbern J., Grossman R.I. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J.Magn. Reson. Imaging 2009, 29:537-544.
35. Habib C.A., Liu M., Bawany N., Garbern J., Krumbein I., Mentzel H.J., Reichenbach J., Magnano C., Zivadinov R., Haacke E.M. Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls. AJNR Am. J. Neuroradiol. 2012, 33:252-258.
36. Hagemeier J., Heininen-Brown M., Poloni G.U., Bergsland N., Magnano C.R., Durfee J., Kennedy C., Carl E., Weinstock-Guttman B., Dwyer M.G., Zivadinov R. Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J.Magn. Reson. Imaging 2012, 36:73-83.
37. Hagemeier J., Weinstock-Guttman B., Bergsland N., Heininen-Brown M., Carl E., Kennedy C., Magnano C., Hojnacki D., Dwyer M.G., Zivadinov R. Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am. J. Neuroradiol. 2012, 33:1596-1601.
38. Hagemeier J., Weinstock-Guttman B., Heininen-Brown M., Poloni G.U., Bergsland N., Schirda C., Magnano C.R., Kennedy C., Carl E., Dwyer M.G., Minagar A., Zivadinov R. Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Front. Biosci. (Elite Ed) 2013, 5:525-532.
39. Hagemeier J., Yeh E.A., Brown M.H., Bergsland N., Dwyer M.G., Carl E., Weinstock-Guttman B., Zivadinov R. Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Mult. Scler. 2013, 19:567-576.
40. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J.Neurochem. 1958, 3:41-45.
41. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J.Neurochem. 2006, 97:1634-1658.
42. Hametner S., Wimmer I., Haider L., Pfeifenbring S., Brück W., Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. 2013, 74:848-861.
43. Hammond K.E., Metcalf M., Carvajal L., Okuda D.T., Srinivasan R., Vigneron D., Nelson S.J., Pelletier D. Quantitative invivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann. Neurol. 2008, 64:707-713.
44. Khalil M., Enzinger C., Langkammer C., Tscherner M., Wallner-Blazek M., Jehna M., Ropele S., Fuchs S., Fazekas F. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult. Scler. 2009, 15:1048-1054.
45. Khalil M., Langkammer C., Ropele S., Petrovic K., Wallner-Blazek M., Loitfelder M., Jehna M., Bachmaier G., Schmidt R., Enzinger C., Fuchs S., Fazekas F. Determinants of brain iron in multiple sclerosis: a quantitative 3T MRI study. Neurology 2011, 77:1691-1697.
46. Khalil M., Teunissen C., Langkammer C. Iron and neurodegeneration in multiple sclerosis. Mult. Scler. Int. 2011, 2011:606807.
47. Langemann H., Kabiersch A., Newcombe J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur. Neurol. 1992, 32:248-252.
48. Langkammer C., Krebs N., Goessler W., Scheurer E., Ebner F., Yen K., Fazekas F., Ropele S. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010, 257:455-462.
49. Lebel R.M., Eissa A., Seres P., Blevins G., Wilman A.H. Quantitative high-field imaging of sub-cortical gray matter in multiple sclerosis. Mult. Scler. 2012, 18:433-441.
50. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., Ellrichmann G., Brück W., Dawson K., Goelz S., Wiese S., Scannevin R.H., Lukashev M., Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
51. Lynch S.G., Fonseca T., Levine S.M. Amultiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol. Biol. 2000, 46:865-869.
52. Madsen E., Gitlin J.D. Copper and iron disorders of the brain. Annu. Rev. Neurosci. 2007, 30:317-337.
53. Mancuso M., Davidzon G., Kurlan R.M., Tawil R., Bonilla E., Di Mauro S., Powers J.M. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J.Neuropathol. Exp. Neurol. 2005, 64:280-294.
54. Markowitz C.E., Spitsin S., Zimmerman V., Jacobs D., Udupa J.K., Hooper D.C., Koprowski H. The treatment of multiple sclerosis with inosine. J.Altern. Complement. Med. 2009, 15:619-625.
55. Marracci G.H., Jones R.E., McKeon G.P., Bourdette D.N. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J.Neuroimmunol. 2002, 13:104-114.
56. Massacesi L., Abbamondi A.L., Giorgi C., Sarlo F., Lolli F., Amaducci L. Suppression of experimental allergic encephalomyelitis by retinoic acid. J.Neurol. Sci. 1987, 80:55-64.
57. Mehta V., Pei W., Yang G., Li S., Swamy E., Boster A., Schmalbrock P., Pitt D. Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013, 8:e57573.
58. Moos T., Rosengren Nielsen T., Skjorringe T., Morgan E.H. Iron trafficking inside the brain. J.Neurochem. 2007, 103:1730-1740.
59. Neema M., Arora A., Healy B.C., Guss Z.D., Brass S.D., Duan Y., Buckle G.J., Glanz B.I., Stazzone L., Khoury S.J., Weiner H.L., Guttmann C.R., Bakshi R. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J.Neuroimaging 2009, 19:3-8.
60. Neema M., Ceccarelli A., Jackson J., Bakshi R. Magnetic resonance imaging in multiple sclerosis. Multiple Sclerosis: Diagnosis and Therapy 2012, 136-162. Wiley-Blackwell, West Sussex, England. H. Weiner, J. Stankiewicz (Eds.).
61. Neema M., Stankiewicz J., Arora A., Dandamudi V.S., Batt C.E., Guss Z.D., Al-Sabbagh A., Bakshi R. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J.Neuroimaging 2007, 17:16S-21S.
62. Oliveira S.R., Kallaur A.P., Simão A.N., Morimoto H.K., Lopes J., Panis C., Petenucci D.L., da Silva E., Cecchini R., Kaimen-Maciel D.R., Reiche E.M. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J.Neurol. Sci. 2012, 321:49-53.
63. Pantopoulos K., Porwal S.K., Tartakoff A., Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012, 51:5705-5724.
64. Pawate S., Wang L., Song Y., Sriram S. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. J.Neuroimaging 2012, 22:137-144.
65. Pedchenko T.V., LeVine S.M. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J.Neuroimmunol. 1999, 84:188-197.
66. Pinero D., Connor J. Iron in the brain: an important contributor in normal and diseased states. Neuroscientist 2000, 6:435-453.
67. Pitt D., Boster A., Pei W., Wohleb E., Jasne A., Zachariah C.R., Rammohan K., Knopp M.V., Schmalbrock P. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch. Neurol. 2010, 67:812-818.
68. Ropele S., de Graaf W., Khalil M., Wattjes M.P., Langkammer C., Rocca M.A., Rovira A., Palace J., Barkhof F., Filippi M., Fazekas F. MRI assessment of iron deposition in multiple sclerosis. J.Magn. Reson. Imaging 2011, 34:13-21.
69. Rouault T.A. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol. 2006, 2:406-414.
70. Rouault T.A., Cooperman S. Brain iron metabolism. Semin. Pediatr. Neurol. 2006, 13:142-148.
71. Rumzan R., Wang J.J., Zeng C., Chen X., Li Y., Luo T., Lv F., Wang Z.P., Hou H., Huang F. Iron deposition in the precentral grey matter in patients with multiple sclerosis: a quantitative study using susceptibility-weighted imaging. Eur. J. Radiol. 2013, 82:e95-e99.
72. Schenck J.F., Zimmerman E.A. High-field magnetic resonance imaging of brain iron: birth of a biomarker?. NMR Biomed. 2004, 17:433-445.
73. Shindler K.S., Ventura E., Dutt M., Elliott P., Fitzgerald D.C., Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J.Neuroophthalmol. 2010, 30:328-339.
74. Skjørringe T., Møller L.B., Moos T. Impairment of interrelated iron- and copper homeostatic mechanisms in brain contributes to the pathogenesis of neurodegenerative disorders. Front. Pharmacol. 2012, 3:169.
75. Spitsin S.V., Scott G.S., Mikheeva T., Zborek A., Kean R.B., Brimer C.M., Koprowski H., Hooper D.C. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic. Biol. Med. 2002, 33:1363-1371.
76. Stankiewicz J., Panter S.S., Neema M., Arora A., Batt C.E., Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4:371-386.
77. Stankiewicz J.M., Brass S.D. Role of iron in neurotoxicity: a cause for concern in the elderly?. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:22-29.
78. Tjoa C.W., Benedict R.H., Weinstock-Guttman B., Fabiano A.J., Bakshi R. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J.Neurol. Sci. 2005, 234:17-24.
79. Van der Worp H.B., Thomas C.E., Kappelle L.J., Hoffman W.P., de Wildt D.J., Bär P.R. Inhibition of iron-dependent and ischemia-induced brain damage by the alpha tocopherol analogue MDL74,722. Exp. Neurol. 1999, 155:103-108.
80. Walsh A.J., Blevins G., Lebel R.M., Seres P., Emery D.J., Wilman A.H. Longitudinal MR imaging of iron in multiple sclerosis: an imaging marker of disease. Radiology 2014, 270:186-196.
81. Walsh A.J., Lebel R.M., Eissa A., Blevins G., Catz I., Lu J.Q., Resch L., Johnson E.S., Emery D.J., Warren K.G., Wilman A.H. Multiple sclerosis: validation of MR imaging for quantification and detection of iron. Radiology 2013, 267:531-542.
82. Wang J., Ren Z., Xu Y., Xiao S., Meydani S.N., Wu D. Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets. Am. J. Pathol. 2012, 180:221-234.
83. Weilbach F.X., Chan A., Toyka K.V., Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2004, 135:49-55.
84. Willenborg D.O., Bowern N.A., Danta G., Doherty P.C. Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen. J.Neuroimmunol. 1988, 17:127-135.
85. Xie L., Li X.K., Funeshima-Fuji N., Kimura H., Matsumoto Y., Isaka Y., Takahara S. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int. Immunopharmacol. 2009, 9:575-581.
86. Xin J., Feinstein D.L., Hejna M.J., Lorens S.A., McGuire S.O. Beneficial effects of blueberries in experimental autoimmune encephalomyelitis. J.Agric. Food Chem. 2012, 60:5743-5748.
87. Yao B., Bagnato F., Matsuura E., Merkle H., van Gelderen P., Cantor F.K., Duyn J.H. Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012, 262:206-215.
88. Zhang Y., Metz L.M., Yong V.W., Mitchell J.R. 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study. J.Neurol. Sci. 2010, 297:76-81.
89. Zhang Y., Zabad R., Wei X., Metz L., Hill M., Mitchell J. Deep grey matter "black T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult. Scler. 2007, 13:880-883.
90. Zivadinov R., Heininen-Brown M., Schirda C.V., Poloni G.U., Bergsland N., Magnano C.R., Durfee J., Kennedy C., Carl E., Hagemeier J., Benedict R.H., Weinstock-Guttman B., Dwyer M.G. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012, 59:331-339.